Javascript must be enabled to continue!
Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study
View through CrossRef
Abstract
Objective:
The need for effective nonhormonal treatments for hot flash management without unwanted side effects continues. The primary aim of this pilot study was to evaluate the effect of combining a nonhormonal pharmacologic agent with a behavioral treatment for hot flash reduction.
Methods:
Seventy-one postmenopausal women were randomized to one of four groups: venlafaxine 75 mg + hypnosis (VH) versus venlafaxine 75 mg + sham hypnosis (VSH) versus a placebo pill + hypnosis (PH) versus placebo pill + sham hypnosis (PSH). Women recorded hot flash severity and frequency in a daily diary, in real time. The intrapatient difference in hot flash score (frequency × severity) at 8 weeks was analyzed using a General Estimating Equation model, using VSH as the referent arm, controlling for baseline hot flashes.
Results:
The active arms including PH or VH were not statistically significantly different than VSH (P = 0.34, P = 0.05, respectively). Women in each active arm reported hot flash reductions of about 50%, with the PSH group reporting a 25% reduction. Women receiving the PSH reported statistically significantly smaller reductions in hot flash score than women in the referent VSH arm (P = 0.001). There were no significant negative side effects during the course of the study.
Conclusions:
Hypnosis alone reduced hot flashes equal to venlafaxine alone, but the combination of hypnosis and venlafaxine did not reduce hot flashes more than either treatment alone. More research is needed to clarify whether combining hypnosis with a different antidepressant would provide synergistic benefits.
Ovid Technologies (Wolters Kluwer Health)
Title: Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study
Description:
Abstract
Objective:
The need for effective nonhormonal treatments for hot flash management without unwanted side effects continues.
The primary aim of this pilot study was to evaluate the effect of combining a nonhormonal pharmacologic agent with a behavioral treatment for hot flash reduction.
Methods:
Seventy-one postmenopausal women were randomized to one of four groups: venlafaxine 75 mg + hypnosis (VH) versus venlafaxine 75 mg + sham hypnosis (VSH) versus a placebo pill + hypnosis (PH) versus placebo pill + sham hypnosis (PSH).
Women recorded hot flash severity and frequency in a daily diary, in real time.
The intrapatient difference in hot flash score (frequency × severity) at 8 weeks was analyzed using a General Estimating Equation model, using VSH as the referent arm, controlling for baseline hot flashes.
Results:
The active arms including PH or VH were not statistically significantly different than VSH (P = 0.
34, P = 0.
05, respectively).
Women in each active arm reported hot flash reductions of about 50%, with the PSH group reporting a 25% reduction.
Women receiving the PSH reported statistically significantly smaller reductions in hot flash score than women in the referent VSH arm (P = 0.
001).
There were no significant negative side effects during the course of the study.
Conclusions:
Hypnosis alone reduced hot flashes equal to venlafaxine alone, but the combination of hypnosis and venlafaxine did not reduce hot flashes more than either treatment alone.
More research is needed to clarify whether combining hypnosis with a different antidepressant would provide synergistic benefits.
Related Results
Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study
Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study
ObjectivesTo compare the efficacy of hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors, and to evaluate the feasibility of conducting a cli...
Proprietary Delivery System of a Novel Supplement Reduced Vasomotor Symptoms in Menopausal Women
Proprietary Delivery System of a Novel Supplement Reduced Vasomotor Symptoms in Menopausal Women
Objective: To evaluate a supplement system for the reduction of vasomotor symptoms in menopausal women.
Methods: A prospective, open-label, IRB-approved study was conducted over 12...
MON-005 AN UNUSUAL CASE OF VASOMOTOR SYMPTOMS IN A POST-MENOPAUSAL WOMAN
MON-005 AN UNUSUAL CASE OF VASOMOTOR SYMPTOMS IN A POST-MENOPAUSAL WOMAN
Abstract
Disclosure: R. Akhter: None. W. Akhter: None. A. Zaidi: None. J.L. Gilden: Novartis Pharmaceuticals.
Introduction: Hot flashes are amon...
The Association between Menopause Symptoms and Risk of Postmenopausal Breast Cancer among nonusers of Hormone Therapy
The Association between Menopause Symptoms and Risk of Postmenopausal Breast Cancer among nonusers of Hormone Therapy
ABSTRACT
Background
Hot flashes are a common symptom among women during their menopause transition, likely due to the changes of endogenous hormone levels. Previous research sugge...
IOR Pilot Evaluation in a Brown-Field Fractured Reservoir Using Data Analytics of Reservoir Simulation Results
IOR Pilot Evaluation in a Brown-Field Fractured Reservoir Using Data Analytics of Reservoir Simulation Results
Abstract
A well-designed pilot is instrumental in reducing uncertainty for the full-field implementation of improved oil recovery (IOR) operations. Traditional model...
CN tower lightning flash characteristics based on high-speed imaging
CN tower lightning flash characteristics based on high-speed imaging
The thesis emphasizes the analysis of fifty-eight flashes that struck the CN Tower during the last five years (2013-2017), based on video records of Phantom v5.0 digital high-speed...
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
<p dir="ltr">Most individuals with Parkinson's disease (PD) experience changes in speech, voice or communication. Speech changes often manifest as hypokinetic dysarthria, a m...
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
<p dir="ltr">Most individuals with Parkinson's disease (PD) experience changes in speech, voice or communication. Speech changes often manifest as hypokinetic dysarthria, a m...

